Cargando…

Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer

BACKGROUND: In precision medicine, somatic and germline DNA sequencing are essential to make genome-guided treatment decisions in patients with cancer. However, it can also uncover unsolicited findings (UFs) in germline DNA that could have a substantial impact on the lives of patients and their rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Bijlsma, Rhode, Wouters, Roel, Wessels, Hester, Sleijfer, Stefan, Beerepoot, Laurens, ten Bokkel Huinink, Daan, Cruijsen, Hester, Heijns, Joan, Lolkema, Martijn P, Steeghs, Neeltje, van Voorthuizen, Theo, Vulink, Annelie, Witteveen, Els, Ausems, Margreet, Bredenoord, Annelien, May, Anne M, Voest, Emile
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200077/
https://www.ncbi.nlm.nih.gov/pubmed/32312756
http://dx.doi.org/10.1136/esmoopen-2019-000619
_version_ 1783529269847130112
author Bijlsma, Rhode
Wouters, Roel
Wessels, Hester
Sleijfer, Stefan
Beerepoot, Laurens
ten Bokkel Huinink, Daan
Cruijsen, Hester
Heijns, Joan
Lolkema, Martijn P
Steeghs, Neeltje
van Voorthuizen, Theo
Vulink, Annelie
Witteveen, Els
Ausems, Margreet
Bredenoord, Annelien
May, Anne M
Voest, Emile
author_facet Bijlsma, Rhode
Wouters, Roel
Wessels, Hester
Sleijfer, Stefan
Beerepoot, Laurens
ten Bokkel Huinink, Daan
Cruijsen, Hester
Heijns, Joan
Lolkema, Martijn P
Steeghs, Neeltje
van Voorthuizen, Theo
Vulink, Annelie
Witteveen, Els
Ausems, Margreet
Bredenoord, Annelien
May, Anne M
Voest, Emile
author_sort Bijlsma, Rhode
collection PubMed
description BACKGROUND: In precision medicine, somatic and germline DNA sequencing are essential to make genome-guided treatment decisions in patients with cancer. However, it can also uncover unsolicited findings (UFs) in germline DNA that could have a substantial impact on the lives of patients and their relatives. It is therefore critical to understand the preferences of patients with cancer concerning UFs derived from whole-exome (WES) or whole-genome sequencing (WGS). METHODS: In a quantitative multicentre study, adult patients with cancer (any stage and origin of disease) were surveyed through a digital questionnaire based on previous semi-structured interviews. Background knowledge was provided by showing two videos, introducing basic concepts of genetics and general information about different categories of UFs (actionable, non-actionable, reproductive significance, unknown significance). RESULTS: In total 1072 patients were included of whom 701 participants completed the whole questionnaire. Overall, 686 (85.1%) participants wanted to be informed about UFs in general. After introduction of four UFs categories, 113 participants (14.8%) changed their answer: 718 (94.2%) participants opted for actionable variants, 537 (72.4%) for non-actionable variants, 635 (87.0%) participants for UFs of reproductive significance and 521 (71.8%) for UFs of unknown significance. Men were more interested in receiving certain UFs than women: non-actionable: OR 3.32; 95% CI 2.05 to 5.37, reproductive significance: OR 1.97; 95% CI 1.05 to 3.67 and unknown significance: OR 2.00; 95% CI 1.25 to 3.21. In total, 244 (33%) participants conceded family members to have access to their UFs while still alive. 603 (82%) participants agreed to information being shared with relatives, after they would pass away. CONCLUSION: Our study showed that the vast majority of patients with cancer desires to receive all UFs of genome testing, although a substantial minority does not wish to receive non-actionable findings. Incorporation of categories in informed consent procedures supports patients in making informed decisions on UFs.
format Online
Article
Text
id pubmed-7200077
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-72000772020-05-06 Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer Bijlsma, Rhode Wouters, Roel Wessels, Hester Sleijfer, Stefan Beerepoot, Laurens ten Bokkel Huinink, Daan Cruijsen, Hester Heijns, Joan Lolkema, Martijn P Steeghs, Neeltje van Voorthuizen, Theo Vulink, Annelie Witteveen, Els Ausems, Margreet Bredenoord, Annelien May, Anne M Voest, Emile ESMO Open Original Research BACKGROUND: In precision medicine, somatic and germline DNA sequencing are essential to make genome-guided treatment decisions in patients with cancer. However, it can also uncover unsolicited findings (UFs) in germline DNA that could have a substantial impact on the lives of patients and their relatives. It is therefore critical to understand the preferences of patients with cancer concerning UFs derived from whole-exome (WES) or whole-genome sequencing (WGS). METHODS: In a quantitative multicentre study, adult patients with cancer (any stage and origin of disease) were surveyed through a digital questionnaire based on previous semi-structured interviews. Background knowledge was provided by showing two videos, introducing basic concepts of genetics and general information about different categories of UFs (actionable, non-actionable, reproductive significance, unknown significance). RESULTS: In total 1072 patients were included of whom 701 participants completed the whole questionnaire. Overall, 686 (85.1%) participants wanted to be informed about UFs in general. After introduction of four UFs categories, 113 participants (14.8%) changed their answer: 718 (94.2%) participants opted for actionable variants, 537 (72.4%) for non-actionable variants, 635 (87.0%) participants for UFs of reproductive significance and 521 (71.8%) for UFs of unknown significance. Men were more interested in receiving certain UFs than women: non-actionable: OR 3.32; 95% CI 2.05 to 5.37, reproductive significance: OR 1.97; 95% CI 1.05 to 3.67 and unknown significance: OR 2.00; 95% CI 1.25 to 3.21. In total, 244 (33%) participants conceded family members to have access to their UFs while still alive. 603 (82%) participants agreed to information being shared with relatives, after they would pass away. CONCLUSION: Our study showed that the vast majority of patients with cancer desires to receive all UFs of genome testing, although a substantial minority does not wish to receive non-actionable findings. Incorporation of categories in informed consent procedures supports patients in making informed decisions on UFs. BMJ Publishing Group 2020-04-19 /pmc/articles/PMC7200077/ /pubmed/32312756 http://dx.doi.org/10.1136/esmoopen-2019-000619 Text en © Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research
Bijlsma, Rhode
Wouters, Roel
Wessels, Hester
Sleijfer, Stefan
Beerepoot, Laurens
ten Bokkel Huinink, Daan
Cruijsen, Hester
Heijns, Joan
Lolkema, Martijn P
Steeghs, Neeltje
van Voorthuizen, Theo
Vulink, Annelie
Witteveen, Els
Ausems, Margreet
Bredenoord, Annelien
May, Anne M
Voest, Emile
Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer
title Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer
title_full Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer
title_fullStr Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer
title_full_unstemmed Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer
title_short Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer
title_sort preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200077/
https://www.ncbi.nlm.nih.gov/pubmed/32312756
http://dx.doi.org/10.1136/esmoopen-2019-000619
work_keys_str_mv AT bijlsmarhode preferencestoreceiveunsolicitedfindingsofgermlinegenomesequencinginalargepopulationofpatientswithcancer
AT woutersroel preferencestoreceiveunsolicitedfindingsofgermlinegenomesequencinginalargepopulationofpatientswithcancer
AT wesselshester preferencestoreceiveunsolicitedfindingsofgermlinegenomesequencinginalargepopulationofpatientswithcancer
AT sleijferstefan preferencestoreceiveunsolicitedfindingsofgermlinegenomesequencinginalargepopulationofpatientswithcancer
AT beerepootlaurens preferencestoreceiveunsolicitedfindingsofgermlinegenomesequencinginalargepopulationofpatientswithcancer
AT tenbokkelhuininkdaan preferencestoreceiveunsolicitedfindingsofgermlinegenomesequencinginalargepopulationofpatientswithcancer
AT cruijsenhester preferencestoreceiveunsolicitedfindingsofgermlinegenomesequencinginalargepopulationofpatientswithcancer
AT heijnsjoan preferencestoreceiveunsolicitedfindingsofgermlinegenomesequencinginalargepopulationofpatientswithcancer
AT lolkemamartijnp preferencestoreceiveunsolicitedfindingsofgermlinegenomesequencinginalargepopulationofpatientswithcancer
AT steeghsneeltje preferencestoreceiveunsolicitedfindingsofgermlinegenomesequencinginalargepopulationofpatientswithcancer
AT vanvoorthuizentheo preferencestoreceiveunsolicitedfindingsofgermlinegenomesequencinginalargepopulationofpatientswithcancer
AT vulinkannelie preferencestoreceiveunsolicitedfindingsofgermlinegenomesequencinginalargepopulationofpatientswithcancer
AT witteveenels preferencestoreceiveunsolicitedfindingsofgermlinegenomesequencinginalargepopulationofpatientswithcancer
AT ausemsmargreet preferencestoreceiveunsolicitedfindingsofgermlinegenomesequencinginalargepopulationofpatientswithcancer
AT bredenoordannelien preferencestoreceiveunsolicitedfindingsofgermlinegenomesequencinginalargepopulationofpatientswithcancer
AT mayannem preferencestoreceiveunsolicitedfindingsofgermlinegenomesequencinginalargepopulationofpatientswithcancer
AT voestemile preferencestoreceiveunsolicitedfindingsofgermlinegenomesequencinginalargepopulationofpatientswithcancer